Clinical Trials Browser

Active not recruiting × Ovarian Neoplasms × surufatinib × Clear all

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

Ovarian Neoplasms